A novel mutation in ICOS presenting as hypogammaglobulinemia with susceptibility to opportunistic pathogens - 04/09/15
Doi : 10.1016/j.jaci.2014.12.1940
Janet Chou, MD a, ∗, Michel J. Massaad, PhD a, ∗, Brittney Cangemi, BA a, Wayne Bainter, BA a, Craig Platt, MD, PhD a, Yousef R. Badran, MD a, Bram P. Raphael, MD b, Daniel S. Kamin, MD b, Jeffrey D. Goldsmith, MD c, Sung-Yun Pai, MD d, e, Waleed Al-Herz, MD f, Raif S. Geha, MD a 
a Division of Immunology, Boston Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, Mass
b Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, Mass
c Department of Pathology, Boston Children's Hospital and Beth Israel Deaconess Medical Center, Boston, Mass
d Division of Hematology-Oncology, Boston Children's Hospital, Boston, Mass
e Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Mass
f Faculty of Medicine, Department of Pediatrics, Kuwait University, Kuwait City, Kuwait
| This study was supported by the National Institutes of Health (grant nos. P01AI-076210 and AI-094017), a grant from the Dubai Harvard Foundation for Medical Research (R.S.G.), a Jeffrey Modell Foundation Translational Research Program Grant Award (J.C.), and a grant from the Kuwait Foundation for the Advancement of Sciences (grant no. 2010-1302-05 to W.A-H.). |
|
| Disclosure of potential conflict of interest: J. Chou has received research support from the Jeffrey Modell Foundation and is employed by Boston Children's Hospital. S.-Y. Pai has received research support from the National Institutes of Health (NIH). R. S. Geha has received research support from the NIH and the Dubai Harvard Foundation for Medical Research and is employed by Boston Children's Hospital. J. D. Goldsmith has received consultancy fees from Cohera Medical, is employed by Beth Israel Deaconess Medical Center and Children's Hospital Boston, has provided expert testimony for various entities, and has received lecture fees from the College of American Pathologists. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2015
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 136 - N° 3
P. 794 - septembre 2015 Retour au numéro
Article précédent
- Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis
- Taylor A. Doherty, Rachel Baum, Robert O. Newbury, Tom Yang, Ranjan Dohil, Melissa Aquino, Ashmi Doshi, Hannah H. Walford, Richard C. Kurten, David H. Broide, Seema Aceves
- Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma
- Ursula Homburg, Harald Renz, Wolfgang Timmer, Jens M. Hohlfeld, Friedeborg Seitz, Katrin Lüer, Alexandra Mayer, Anja Wacker, Oliver Schmidt, Jens Kuhlmann, Agnieszka Turowska, Julia Roller, Klaus Kutz, Gerhard Schlüter, Norbert Krug, Holger Garn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?